Divi’s Lab Q4 Results 2025: Q4 FY25 PAT grows 23% and Revenue Zooms to ₹2,585 crores; ₹30/share Dividend Declared

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Mon May 19 2025

Divi’s Lab Q4 Results 2025: Q4 FY25 PAT grows 23% and Revenue Zooms to ₹2,585 crores; ₹30/share Dividend Declared

Divi’s Lab reported its Q4 and full-year financials for the FY 2025 on 17th May 2025. Divi’s Lab posted 23% PAT growth in Q4 FY25, with net profits standing at ₹662 crores against the figure of ₹538 crores in Q4 FY24. The company’s revenue from operations for the 3 months ending March 2025 was ₹2,858 crores, 12.26% higher than the revenue of ₹2,303 crores in Q4 FY24.

Divi’s Laboratory Q4 Results 2025 show that for the full year, the company’s revenue has risen by 19.31% from ₹7,854 crores in Q4 FY25 to ₹9,360 crores. On the profit side, the pharma manufacturer earned a PAT of ₹2,191 crores in FY25, registering a 36.93% YoY growth.

Table of Contents

Divi’s Laboratory Q4 Results 2025: Extract Quarterly Financials

Particular	Quarter Ended		Year Ended
Particular	31 – 03 – 2025	31 – 03 – 2024	31 – 03 – 2025	31-03-2024
Revenue From Operations	₹2,585	₹2,303	₹9,360	₹7,845
Profit Before Tax (PBT)	₹864	₹713	₹2,916	₹2,163
Net Profit	₹662	₹538	₹2,191	₹1,600
EPS (Basic)	₹24.93	₹20.25	₹82.53	₹60.27
EPS (Diluted)	₹24.93	₹20.25	₹82.53	₹60.27

*figures in crores expect EPS

#loss or negative values are denoted in brackets

Divi’s Lab Q4 Results 2025 Highlights: Consolidated Figures

Divi’s Lab posted a net profit of ₹662 crores in Q4 FY25, up by 23% compared to PAT of ₹538 crores in the corresponding period in FY24.
The company’s revenue from operations for the period under review was ₹2,585 crores, rising by 282 crores from ₹2,303 crores in Q4 FY25.
The Board of Divi’s Laboratory has approved a dividend of ₹30 per share (1500%) of face value ₹ 2 each.
The standalone net profit of Divi’s Lab in Q4 was ₹667 crores, against a revenue from operations of ₹2,536 crores.

Divi’s Laboratory Share Price Performance

On the opening bell of 19th May 2025, shares of Divi’s Laboratory Limited commenced trading at an opening price of ₹6,400.00. After the Q4 earnings announcement on 17th May 2025, the stock offered gains of up to 6% today (19th May 2025), creating a day and 52-week high of ₹6,705.00. On the closing of the trading session at 3:30 PM, Divi’s Lab shares closed at a level of ₹6,567.50 a share, offering closing returns of 4.59%.

Final Thoughts on Divi’s Lab Q4 Results 2025

Divi’s Laboratories is engaged in the manufacturing of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients. The company posted its FY25 results on Saturday, 17th May 2025, showcasing exceptional profitability and revenue growth. Divi’s strong Q4 financial performance can be attributed to a balanced growth in generics, custom synthesis and Nutracueticals. As per Jeffeires India, the company’s results aligned with the analyst estimates, and the rating agency maintains a “HOLD” rating for Divi’s Laboratory Limited.

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.